Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned an average rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.57.
Several research firms have commented on YMAB. HC Wainwright boosted their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Canaccord Genuity Group increased their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. BMO Capital Markets lifted their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 target price (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th.
Check Out Our Latest Stock Report on Y-mAbs Therapeutics
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Trexquant Investment LP increased its stake in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after acquiring an additional 61,785 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Y-mAbs Therapeutics by 24.0% in the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after buying an additional 157,173 shares during the period. GSA Capital Partners LLP raised its holdings in Y-mAbs Therapeutics by 208.3% in the 3rd quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after buying an additional 92,765 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $34,000. Finally, Massachusetts Financial Services Co. MA boosted its stake in Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock worth $448,000 after buying an additional 59,201 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.
Y-mAbs Therapeutics Stock Performance
Shares of NASDAQ YMAB opened at $15.14 on Wednesday. The firm has a fifty day moving average of $15.64 and a 200 day moving average of $10.02. The firm has a market cap of $662.83 million, a PE ratio of -30.90 and a beta of 0.74. Y-mAbs Therapeutics has a one year low of $4.60 and a one year high of $20.90.
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. The business had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. On average, equities analysts predict that Y-mAbs Therapeutics will post -0.43 EPS for the current fiscal year.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Further Reading
- Five stocks we like better than Y-mAbs Therapeutics
- What Investors Need to Know About Upcoming IPOs
- Silicon Motion Proves That AI in Motion Stays in Motion
- Investing In Preferred Stock vs. Common Stock
- Undervalued UnitedHealth Group Won’t Be For Long
- Trading Halts Explained
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.